FDA recall record

IntegraDose Compounding Services Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for recall — FDA D-0015-2026

Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.

Class Iclassification
D-0015-2026official record ID
Oct 22, 2025report date

Recall record at a glance

Official recordD-0015-2026
CategoryDrug Recalls
ClassificationClass I
FDA record statusOngoing
Recalling firmIntegraDose Compounding Services LLC
Report dateOct 22, 2025
Recall initiation dateSep 16, 2025
Quantity853/500 mL bags
LocationMinneapolis, MN, United States

Official product description

Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for intravenous use, Rx only, IntegraDose Compounding Services LLC, 719 Kasota Ave Se, Minneapolis, MN 55414-2842 NDC 71139-0012-1

Why the product was recalled

Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.

Distribution information

Nationwide in the USA

How to read the classification

FDA Class I indicates a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. The classification shown here comes directly from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.